Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Panel of 18 Biochemical Tests Rapidly Identifies Staphylococcus

By Labmedica staff writers
Posted on 18 Feb 2008
A panel of 18 tests has been launched for the biochemical identification of Staphylococcus species and related organisms isolated from human clinical specimens.

Called Remel RapID Staph Plus, the rapid manual identification system offers clinical laboratories of any size a valuable new diagnostic tool for an important group of opportunistic pathogens. More...
All of the test wells are inoculated simultaneously and the panel is then incubated aerobically for four hours.

Resultant color reactions are easy to read and are used to identify the organism using the RapID Staph Plus color guide, which helps generate a numeric microcode. The microcode is entered into Windows-based software for organism identification. This user-friendly package contains a comprehensive database of 40 medically important Staphylococcus species and related organisms, and ranks identifications by probability (greater than 95% probability is required for species level identification), ensuring accuracy and reliability.

The RapID Staph Plus can identify Staphylococcus aureus and over 30 species of coagulase negative staphylococci (CNS) in addition to other related organisms. CNS are an increasingly important cause of nosocomial infections. They are the most common causal agents of bacteraemia in patients with indwelling medical devices and are one of the most common causes of septicemia in pediatric patients.

RapID Staph Plus was developed by Oxoid (Basingstoke, UK

Julie Elston, clinical products application manager at Oxoid, commented, "The serious nature of bacteraemia means that there is little time to spare in determining the best course of action. Long delays simply are [not] acceptable and, as a result, the empiric use of agents such as vancomycin is common. RapID Staph Plus gives rapid, same-day results, allowing appropriate therapy to be determined more quickly and providing an opportunity for the use of vancomycin to be restricted to only when it is absolutely necessary.”

Oxoid's RapID range includes products for the identification of oxidase-negative Enterobacteriaceae, anaerobic bacteria, Gram-negative glucose non-fermenters, Corynebacterium species, Neisseria and Haemophilus (common in urinary infections), yeasts and related organisms, and Streptococci and related organisms.


Related Links:
Oxoid

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.